| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6410524 | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
Nov, 2019
(4 years ago) | |
| US6747020 | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
Nov, 2019
(4 years ago) | |
| US6410054 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US6534093 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US7157101 | UPJOHN | Micronized eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US6495165 | UPJOHN | Eplerenone compositions having improved bioavailability |
Dec, 2019
(4 years ago) | |
| US6558707 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(4 years ago) | |
| US6863902 | UPJOHN | Immediate release eplerenone compositions |
Apr, 2020
(4 years ago) | |
|
US6747020 (Pediatric) | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
May, 2020
(3 years ago) | |
|
US6410524 (Pediatric) | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
May, 2020
(3 years ago) | |
|
US6558707 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US7157101 (Pediatric) | UPJOHN | Micronized eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US6410054 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US6534093 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(3 years ago) | |
|
US6495165 (Pediatric) | UPJOHN | Eplerenone compositions having improved bioavailability |
Jun, 2020
(3 years ago) | |
|
US6863902 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Oct, 2020
(3 years ago) | |
Inspra is owned by Upjohn.
Inspra contains Eplerenone.
Inspra has a total of 16 drug patents out of which 16 drug patents have expired.
Expired drug patents of Inspra are:
- US6410524
- US6747020
- US6410054
- US6534093
- US7157101
- US6495165
- US6558707
- US6863902
- US6747020*PED
- US6410524*PED
- US6558707*PED
- US7157101*PED
- US6410054*PED
- US6534093*PED
- US6495165*PED
- US6863902*PED
Inspra was authorised for market use on 27 September, 2002.
Inspra is available in tablet;oral dosage forms.
Inspra can be used as use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor (and optionally a diuretic) for treating congestive heart failure and hypertension, treatment of conditions related to hyperaldosteronism such as hypertension and cardiac insufficiency, with eplerenone, use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor for treating hypertension, treatment of conditions for which an aldosterone receptor blocker is indicated, such as hypertension, heart failure, and post-myocardial infarction, treatment of hypertension.
The generics of Inspra are possible to be released after 10 October, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jul 31, 2011 |
Drugs and Companies using EPLERENONE ingredient
Market Authorisation Date: 27 September, 2002
Treatment: Use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor for treating hypertension; Use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor...
Dosage: TABLET;ORAL
INSPRA family patents
